This upcoming Sunday, the people of Venezuela will hold an election that, if legitimate, would put an end to years of the oppressive Maduro narco-regime. U.S. Senator Marco Rubio (R-FL) issued a statement in support of the Venezuelan people: “The...
News
Latest News
Rubio: “La Tenacidad y Valentía del Pueblo venezolano Estarán a la Vista”
Este próximo domingo, el pueblo venezolano tendrá una elección que, de ser legítima, pondría fin a años de opresión por parte del narco-régimen de Maduro. El senador estadounidense Marco Rubio (R-FL) grabó un mensaje de video en español y emitió una declaración en...
Rubio, Scott, Colleagues to Biden Admin: No Privileges Should Be Given to 9/11 Terrorist
Twenty-three years ago, the United States was attacked by Islamic terrorists on September 11, 2001. Now, Zacarias Moussaoui, the only person convicted in a U.S. court for his role in the attack, has requested the U.S. Department of Justice to allow a prisoner transfer...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
Rubio, Colleagues Introduce Ensuring Continuity in Veterans’ Health Act
As the U.S. Department of Veterans Affairs (VA) opens up new facilities, many veterans are losing access to the VA’s Community Care Program and, consequently, their long-term healthcare providers. Veterans throughout the country have reported a loss of care, including...
Rubio Introduces Bill to Strengthen U.S.-India Security Partnership
The U.S.-India partnership is vital to countering influences from Communist China. In order to strengthen this partnership, it is essential to enhance our strategic diplomatic, economic, and military relationship with New Delhi. U.S. Senator Marco Rubio (R-FL)...
Rubio: FDA’s Abortion Pill Policy Violates Federal Law
On January 3, 2023, the U.S. Food and Drug Administration (FDA) began allowing pharmacies, including mail-in services, to distribute the chemical abortion pill mifepristone with no in-person distribution requirement. Data shows mifepristone is dangerous, which is why women were previously required to use the drug under medical supervision.
On January 31, U.S. Senator Marco Rubio (R-FL) and U.S. Representative Andrew Clyde (R-GA) sent a letter to the Government Accountability Office (GAO) arguing the FDA’s new guidance may constitute a “rule” and thereby be subject to Congressional review under the Congressional Review Act (CRA).
GAO has yet to respond with its conclusion. Meanwhile, after careful consideration, Rubio and Clyde have determined the FDA’s new guidance does indeed constitute a “rule,” and that by failing to submit a report to Congress, the FDA violated the CRA. They sent their analysis to GAO in a letter.
- “We believe the FDA’s updated REMS for mifepristone is a ‘rule’ under CRA because it has general applicability; has future effect; implements or prescribes law or policy; and is not subject to the limited exceptions to a ‘rule’ defined by the CRA because it is not a rule of particular applicability; it does not relate to agency management/personnel; and it substantially impacts the rights and duties of non-agency parties.”
- “The FDA did not submit this policy to Congress and we believe it is imperative that all agency rules remain subject to the full spectrum of congressional oversight afforded by law.”
Senators Cindy Hyde-Smith (R-MS), Rick Scott (R-FL), James Lankford (R-OK), and Mike Braun (R-IN), and 15 other members of Congress also signed the letter.